Par Pharmaceutical Co., Inc. (PRX) provided an update on Friday regarding the development status of its three, in-licensed, proprietary pipeline products - pafuramidine, Loramyc, and Zensana. These three products represent the current product pipeline of Strativa Pharmaceuticals, Par's proprietary products division.Earlier this week, Immtech Pharmaceuticals, Inc. announced that after discussion with the U.S. Food and Drug Administration, the pafuramidine program has been placed on clinical hold. In preliminary findings from an in- progress safety study at a South African site, abnormal laboratory values were found in several volunteers following treatment with pafuramidine. Pafuramidine maleate is for pneumocystis pneumonia in AIDS patients.Loramyc, an innovative antifungal therapy for the treatment of oropharyngeal candidiasis, has completed patient enrollment ahead of the pivotal Phase III clinical trial. Trial results are expected in the first half of 2008 and a new drug application is expected to be submitted to FDA in the second half of 2008.Under a development agreement with Novadel Pharma, Inc., Par has completed its reformulation of Zensana, which could be among the first in its class of 5-HT3 antagonist anti-emetic therapies to be available in an oral spray form. The company said that it is preparing for the requisite studies to reconfirm the product's pharmacokinetic profile and confirm stability acceptability. These studies are expected to be completed by the end of 2008 with an NDA to be filed shortly thereafter.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.